Profit for Biotech Giant CSL Rises 7 Percent, Plasma Business Offsets Vaccine Decline

CSL’s plasma and iron deficiency businesses drive strong growth, helping offset vaccine sales decline as US immunisation rates fall.

The SARS-CoV-2 virus in blood plasma. Several IgG antibodies (light blue) are bound to coronavirus spike proteins (red). Juan Gaertner/Shutterstock

Australian biotechnology company CSL reported strong growth in its blood plasma and iron deficiency businesses in the first half of the 2025 financial year.

However, weaker vaccine sales, owing to a drop in United States, weighed on overall performance.